[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT07053046":3,"trial-entities:NCT07053046":103,"trial-summary:NCT07053046":106},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":25,"primary_purpose":14,"phases":26,"enrollment_info":28,"interventions":31,"primary_outcomes":40,"secondary_outcomes":58,"sex":78,"minimum_age":17,"maximum_age":17,"healthy_volunteers":15,"eligibility_criteria":79,"std_ages":86,"locations":90,"central_contacts":99,"overall_officials":100,"references":101,"see_also_links":102},"NCT07053046","250764","PRECIDENTD Engagement Methods for Sites","PRECIDENTD Engagement Methods for Sites (PRECIDENTD-EMS)","ENROLLING_BY_INVITATION","2027-02-28","2026-07","2026-07-29","2025-07-07","Vanderbilt University Medical Center","OTHER",false,"This trial is evaluating approaches to effective stakeholder engagement as part of an ongoing multi-site trial, called PRECIDENTD (PREvention of Cardiovascular and DiabEtic kidNey disease in Type 2 Diabetes). PRECIDENTD is a PCORI-funded trial comparing two classes of medication for reducing major health events (e.g., heart attack, stroke, kidney disease) in patients with type 2 diabetes. This is a trial within PRECIDENTD examining Engagement Methods for Sites (PRECIDENTD-EMS) in which PRECIDENTD study sites are randomized to agile engagement methods or a standard engagement approach. The application of agile methods will provide opportunities for increased collaboration between patient partners and study sites during the conduct of the study. The hypothesis is that this will result in better research outcomes for the larger PRECIDENTD study, as well as engagement quality and partner outcomes among those engaged with the conduct of the PRECIDENTD study, as compared with a standard engagement approach.\n\nThis study is designed to assess if agile methodology - when applied to engagement during the conduct of a study - will affect research outcomes of that study, as well as the quality of engagement.\n\nAim 1: Evaluate whether agile methods applied to stakeholder engagement impact research outcomes. The investigators will compare research outcomes (recruitment, adherence to assigned medication, and retention in the larger PRECIDENTD study) between study sites in the agile and standard engagement arms.\n\nAim 2. Evaluate whether agile methods in stakeholder engagement impact partners and identify potential mediators of effects. The investigators will examine engagement quality and partner outcomes between the agile and standard engagement arms. The investigators will also explore engagement quality as a potential driver\u002Fmediator of the effects of agile methods on partner outcomes.",null,[19],"Stakeholder Engagement",[21,22,23,24],"Stakeholders","Engagement","Agile Methods","Patient Partners","INTERVENTIONAL",[27],"NA",{"count":29,"type":30},165,"ESTIMATED",[32,36],{"type":14,"name":33,"description":34,"armGroupLabels":35},"Standard engagement approach","Large group meetings led by PRECIDENTD PIs; composed of \\~20 sites (with \\~25 site investigators and \\~40 study staff). PRECIDENTD PIs will share updates and facilitate discussion around any problems.\n\nProblem identification and steps toward solution occur sequentially. A problem is identified in the data (e.g., slow recruitment), then brought to the Stakeholder Advisory Council (SAC) for advisement, then back to site investigators and study staff to implement recommended changes, the PIs look at data to see if changes improved the problem. PIs and the Stakeholder Engagement Core broker information and relationships with SAC partners.",[33],{"type":14,"name":37,"description":38,"armGroupLabels":39},"Agile methods engagement approach","Small group meetings led by a coordinator trained in agile methods; composed of \\~4 sites each (representing 4-6 investigators and 6-10 study staff), plus 2-3 Stakeholder Advisory Council (SAC) patient partners. Meetings will focus on problem-solving around specific topics and apply agile tools and principles.\n\nSites in each small group will review process data together and each site will identify a specific topic (recruitment, retention, medication adherence) to focus on improving over the next month. Research partners at sites and patient partners will contribute to discussion and reflection on barriers, challenges, successes, and facilitators. Steps toward solutions occur on a rapid timeframe, iteratively using data as a guidepost.",[37],[41,45,49,52,55],{"measure":42,"description":43,"timeFrame":44},"Participant Recruitment","Total patient participants enrolled in PRECIDENTD across sites","18 months post-baseline",{"measure":46,"description":47,"timeFrame":48},"Engagement experience","As measured by the Patient Engagement in Research Scale (PEIRS); Procedural requirements and Convenience subscales. Items scored on a scale from 0-5, where higher scores indicate better engagement experiences.","Baseline and 6, 12, and 18 months post-baseline",{"measure":50,"description":51,"timeFrame":48},"Partnership functioning","As measured by the Patient Engagement in Research Scale (PEIRS); Contributions and Support subscales. Items scored on a scale from 0-5, where higher scores indicate better partnership functioning.",{"measure":53,"description":54,"timeFrame":48},"Group dynamics","As measured by the Patient Engagement in Research Scale (PEIRS); Team environment and interaction subscale. Items scored on a scale from 0-5, where higher scores indicate better group dynamics.",{"measure":56,"description":57,"timeFrame":48},"Equity and Inclusiveness","Selected \\& adapted items from the Research Engagement Survey Tool (REST) - Facilitate collaborative, equitable partnerships subscale. Items scored on a scale from 0-5, where higher scores indicate better equity and inclusiveness.",[59,63,66,68,72,75],{"measure":60,"description":61,"timeFrame":62},"Medication adherence","Proportion of PRECIDENTD study participants taking assigned study medication across sites. As assessed by participant self-report via communication with study sites and study assessments.","Baseline and 18 months",{"measure":64,"description":65,"timeFrame":62},"Participant retention","Proportion of PRECIDENTD study participants completing study visits across sites.",{"measure":64,"description":67,"timeFrame":62},"Proportion of PRECIDENTD study participants completing study assessments across sites.",{"measure":69,"description":70,"timeFrame":71},"Post-engagement capacity and readiness","Item developed by the study team. Items scored on a scale from 0-5, where higher scores indicate better post-engagement capacity and readiness.","12 and 18 months post-baseline",{"measure":73,"description":74,"timeFrame":48},"Costs and benefits","Selected \\& adapted items from the Patient Engagement in Research Scale (PEIRS); Benefits subscale. Items scored on a scale from 0-5, where higher scores indicate better benefits.",{"measure":76,"description":77,"timeFrame":71},"Engagement Sustainability","Selected \\& adapted items from the REST - Partnership sustainability to meet goals and objectives. Items scored on a scale from 0-5, where higher scores indicate better engagement sustainability.","ALL",{"inclusion":80,"exclusion":84,"raw_text":85},[81,82,83],"PRECIDENTD patient stakeholder advisory council partners","PRECIDENTD site study staff","PRECIDENTD site investigators",[],"Inclusion Criteria:\n\n* PRECIDENTD patient stakeholder advisory council partners\n* PRECIDENTD site study staff\n* PRECIDENTD site investigators",[87,88,89],"CHILD","ADULT","OLDER_ADULT",[91],{"facility":13,"city":92,"state":93,"zip":94,"country":95,"geoPoint":96},"Nashville","Tennessee","37203","United States",{"lat":97,"lon":98},36.16589,-86.78444,[],[],[],[],{"nct_id":4,"conditions":104,"biomarkers":105},[19],[],{"nct_id":4,"found":15,"summary":17,"prompt_version":17}]